Tag Archives: JCTCF

Top Value Stocks To Own For 2019

Xact Kapitalforvaltning AB raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 261,826 shares of the biopharmaceutical company’s stock after buying an additional 11,835 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in Gilead Sciences were worth $19,739,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business.....More>>>

Top 5 Value Stocks To Watch For 2019

Apple Hospitality REIT Inc (NYSE:APLE) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $16.67 and last traded at $16.70, with a volume of 40427 shares trading hands. The stock had previously closed at $16.88.

Several equities research analysts recently issued reports on the company. ValuEngine lowered Apple Hospitality REIT from a “hold” rating to a “sell” rating in a research note on Monday, June 18th. B. Riley raised Apple Hospitality REIT from a “neutral” rating to a “buy” rating and set a $20.00....More>>>

Top 10 Clean Energy Stocks To Watch Right Now

Things are moving fast in renewable energy. Really fast. Consider that in 2008 wind farms supplied just 1.5% of all electricity in the United States. But by 2019 wind power is expected to contribute 6.9% of American electricity and overtake hydropower as the top renewable energy source.

The rise of wind power wouldn’t have been possible without two companies in particular, which combine to own 20.7 gigawatts of wind capacity, or about 24% of the country’s total. Investors wouldn’t be surprised to learn that clean energy provider NextEra Energy is one of the renewable....More>>>

Top 10 Stocks To Buy Right Now

Analysis focus: OMER

Omeros (NASDAQ:OMER) is moving towards a rolling BLA submission for OMS721. On this good news, and despite tepid Q1 results, investors are becoming increasingly bullish the stock, as seen by its sudden 23% spike on the news of the BLA submission.

OMS721 is in trials for HSCT-TMA. This indication has roughly 2000-2500 patients per year in the US. 721 is also in trials for IgAN, which we have discussed extensively in our articles. Despite competition, which details we presented in these columns earlier, theres a strong case to be made for the drug to be a billion....More>>>